Research Analysts Issue Forecasts for TCRX Q1 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Wedbush issued their Q1 2026 earnings per share (EPS) estimates for shares of TScan Therapeutics in a note issued to investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.23) for the quarter. Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.25) EPS and Q4 2026 earnings at ($0.22) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million.

Several other brokerages have also recently commented on TCRX. Barclays dropped their price target on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. HC Wainwright dropped their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday. Morgan Stanley reissued an “overweight” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $8.50.

TScan Therapeutics Trading Down 6.9 %

TCRX stock opened at $1.29 on Thursday. The business’s 50-day moving average is $1.49 and its 200 day moving average is $2.72. TScan Therapeutics has a 12-month low of $1.02 and a 12-month high of $9.69. The stock has a market cap of $72.72 million, a price-to-earnings ratio of -1.21 and a beta of 1.06. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TCRX. abrdn plc grew its stake in shares of TScan Therapeutics by 137.8% in the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after buying an additional 512,049 shares during the period. JPMorgan Chase & Co. lifted its holdings in TScan Therapeutics by 94.4% in the third quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company’s stock valued at $158,000 after acquiring an additional 15,441 shares during the last quarter. Barclays PLC grew its position in TScan Therapeutics by 341.1% in the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock worth $289,000 after acquiring an additional 44,903 shares during the period. Prudential Financial Inc. acquired a new stake in TScan Therapeutics during the fourth quarter worth $32,000. Finally, Lynx1 Capital Management LP raised its position in TScan Therapeutics by 2.5% in the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock valued at $16,286,000 after purchasing an additional 132,747 shares during the period. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.